Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors (NCT06128551)
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (55 Sites)
Showing the first 25 of 55 sites.
- City of Hope — Duarte, California
- UC IRVINE Health — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
- University of Colorado Cancer Center — Aurora, Colorado
- Florida Cancer Specialists — Sarasota, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
- Community Health Network — Indianapolis, Indiana
- Dana Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Cancer — Detroit, Michigan
- START Midwest — Grand Rapids, Michigan
- Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Oklahoma — Oklahoma City, Oklahoma
- Allegheny Health Network — Pittsburgh, Pennsylvania
- Sarah Cannon Research Institue — Nashville, Tennessee
- Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
- NEXT Oncology Virginia — Fairfax, Virginia
- West Cancer Institute — Angers,
- Institut Bergonie — Bordeaux,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.